Adjuvant interferon-alpha in malignant melanoma: current status.
High-risk surgically resected primary or loco-regional cutaneous malignant melanoma, although uncommon, can be associated with less than 50% 5-year survival; adjuvant therapy of proven efficacy is therefore appropriate. Since immunological control mechanisms seem to be important in the natural history of melanoma, biological agents have been the subject of many adjuvant studies. Most popular has been recombinant interferon. Well over 4000 patients have been entered into randomized studies. Results suggest that there may be a clinical benefit, most clearly in relapse-free but also perhaps in overall survival. More precise estimates of the magnitude of any benefits are needed. The doses, schedules and cost-benefits have yet to be fully evaluated. Interferon cannot yet be recommended as standard adjuvant therapy in high-risk malignant melanoma.
Hancock
B W
BW
Weston Park Hospital, Sheffield.
Harris
S
S
Wheatley
K
K
Gore
M
M
D003131:Combined Modality Therapy; D006801:Humans; D007167:Immunotherapy; D007370:Interferon Type I / Q000627:therapeutic use*; D008545:Melanoma / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000628:therapy*
D007370:Interferon Type I; D011994:Recombinant Proteins